SG Americas Securities LLC Lowers Stake in Genmab A/S (NASDAQ:GMAB)

SG Americas Securities LLC reduced its stake in shares of Genmab A/S (NASDAQ:GMAB - Free Report) by 60.1% during the 3rd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 14,447 shares of the company's stock after selling 21,787 shares during the period. SG Americas Securities LLC's holdings in Genmab A/S were worth $352,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also made changes to their positions in the company. Sanctuary Advisors LLC purchased a new stake in Genmab A/S during the second quarter worth about $1,354,000. Point72 Asset Management L.P. purchased a new stake in shares of Genmab A/S during the 2nd quarter worth approximately $457,000. Cubist Systematic Strategies LLC grew its holdings in shares of Genmab A/S by 109.7% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 278,541 shares of the company's stock worth $7,000,000 after acquiring an additional 145,689 shares during the period. Benjamin F. Edwards & Company Inc. increased its stake in Genmab A/S by 7.1% in the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 7,227 shares of the company's stock valued at $182,000 after purchasing an additional 478 shares in the last quarter. Finally, Renaissance Technologies LLC raised its holdings in Genmab A/S by 7.6% during the second quarter. Renaissance Technologies LLC now owns 1,462,459 shares of the company's stock worth $36,752,000 after purchasing an additional 103,859 shares during the last quarter. 7.07% of the stock is owned by institutional investors and hedge funds.

Genmab A/S Stock Performance

NASDAQ GMAB traded up $0.02 during mid-day trading on Friday, reaching $22.98. 2,087,791 shares of the stock were exchanged, compared to its average volume of 621,761. The stock has a market capitalization of $15.20 billion, a PE ratio of 19.15, a PEG ratio of 0.71 and a beta of 0.98. Genmab A/S has a 1-year low of $22.52 and a 1-year high of $32.89. The business's fifty day simple moving average is $25.73 and its 200 day simple moving average is $27.08.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last posted its quarterly earnings data on Thursday, August 8th. The company reported $0.22 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.29 by ($0.07). The business had revenue of $779.50 million for the quarter, compared to analyst estimates of $734.60 million. Genmab A/S had a return on equity of 17.48% and a net margin of 29.06%. On average, analysts anticipate that Genmab A/S will post 1.27 EPS for the current year.

Analyst Ratings Changes

Several analysts have weighed in on GMAB shares. HC Wainwright reissued a "buy" rating and issued a $50.00 target price on shares of Genmab A/S in a report on Wednesday. JPMorgan Chase & Co. restated a "neutral" rating on shares of Genmab A/S in a report on Tuesday, August 20th. Truist Financial cut their target price on shares of Genmab A/S from $53.00 to $50.00 and set a "buy" rating for the company in a research report on Monday, September 9th. Royal Bank of Canada upgraded shares of Genmab A/S from a "sector perform" rating to an "outperform" rating in a research report on Monday, July 15th. Finally, Morgan Stanley restated an "equal weight" rating and set a $31.00 price objective on shares of Genmab A/S in a research report on Wednesday, September 11th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and nine have assigned a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $45.20.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.